Glenmark gets FDA green light for generic Welchol
Glenmark Pharmaceuticals has received the OK from the Food and Drug Administration for the generic version of Daiichi Sankyo’s Welchol (colesevelam hydrocholoride) for oral suspension in 1.875 g/packet and 3.75 g/packet.
The product is intended to lower LDL or “bad” cholesterol.
Welchol for oral suspension had a market value of approximately $73 million for the 12 month period ending May 2018, according to IQVIA data.
The product is intended to lower LDL or “bad” cholesterol.
Welchol for oral suspension had a market value of approximately $73 million for the 12 month period ending May 2018, according to IQVIA data.